About us

We are very pleased with our collaborations with NBD, by using their technology we have been able to generate novel chemical entities targeting MAGL, and also we have identified novel binding sites at the CB1R for positive allosteric modulators. Also, the collaboration with NBD has been essential for our last publication in British Journal of Pharmacology.

Professor of Immunology,
Founder and CSO of Emerald Health Biotechnology

We have built up a collaboration with NBD on a novel cancer target and we have been able to find active new chemical entities in a very short period of time.

UB - Cancer Cell Biology Research Group

Through a long-term relationship, we are using the in silico technologies of Nostrum Biodiscovery for studying a range of epigenetics targets to help us speed up our drug discovery programs.

Head of Medicinal Chemistry of Oryzon Genomics

NBD has been key in finding patentable New Chemical Entities for one of our early drug discovery projects.

CEO Senolytic Therapeutics